alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['COL1A1-PDGFB Fusion'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]","['Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans']",LEVEL_1,LEVEL_Fda2,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}",[],"['20439456', '21128251', '15503291', '15746584', '18451237', '15681532', '19620561']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237)."
['COL1A1-PDGFB Fusion'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]","['Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans']",LEVEL_1,LEVEL_Fda2,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}",[],"['20439456', '21128251', '15503291', '15746584', '18451237', '15681532', '19620561']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237)."
['COL1A1-PDGFB Fusion'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]","['Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans']",LEVEL_1,LEVEL_Fda2,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}",[],"['20439456', '21128251', '15503291', '15746584', '18451237', '15681532', '19620561']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237)."
['COL1A1-PDGFB Fusion'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]","['Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans']",LEVEL_1,LEVEL_Fda2,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}",[],"['20439456', '21128251', '15503291', '15746584', '18451237', '15681532', '19620561']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237)."
['COL1A1-PDGFB Fusion'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]","['Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans']",LEVEL_1,LEVEL_Fda2,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}",[],"['20439456', '21128251', '15503291', '15746584', '18451237', '15681532', '19620561']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237)."
['COL1A1-PDGFB Fusion'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]","['Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans']",LEVEL_1,LEVEL_Fda2,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}",[],"['20439456', '21128251', '15503291', '15746584', '18451237', '15681532', '19620561']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237)."
['COL1A1-PDGFB Fusion'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]","['Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans']",LEVEL_1,LEVEL_Fda2,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}",[],"['20439456', '21128251', '15503291', '15746584', '18451237', '15681532', '19620561']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237)."
